Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

Aim Satapoomin; Punyawee Dulyayangkul; Matthew B Avison

doi:10.1128/aac.02179-21

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

Aim Satapoomin, Punyawee Dulyayangkul, Matthew B Avison

Research output: Contribution to journal › Article (Academic Journal) › peer-review

24 Citations (Scopus)

136 Downloads (Pure)

Abstract

We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.

Original language	English
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	66
Issue number	4
DOIs	https://doi.org/10.1128/aac.02179-21
Publication status	Published - 16 Mar 2022

Bibliographical note

Funding Information:
This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research. N.S. received a postgraduate scholarship from the University of Bristol. We declare no conflicts of interest.

Publisher Copyright:
© 2022 American Society for Microbiology. All rights reserved.

Keywords

KPC
carbapenemase

Access to Document

10.1128/aac.02179-21

Full-text PDF (author accepted manuscript)
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via American Society for Microbiology at https://doi.org/10.1128/aac.02179-21. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 223 KBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{7fd2b697f91244488c378c8570ad0528,

title = "Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam",

abstract = "We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.",

keywords = "KPC, carbapenemase",

author = "Aim Satapoomin and Punyawee Dulyayangkul and Avison, \{Matthew B\}",

note = "Funding Information: This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research. N.S. received a postgraduate scholarship from the University of Bristol. We declare no conflicts of interest. Publisher Copyright: {\textcopyright} 2022 American Society for Microbiology. All rights reserved.",

year = "2022",

month = mar,

day = "16",

doi = "10.1128/aac.02179-21",

language = "English",

volume = "66",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "4",

}

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam. / Satapoomin, Aim; Dulyayangkul, Punyawee; Avison, Matthew B.
In: Antimicrobial Agents and Chemotherapy, Vol. 66, No. 4, 16.03.2022.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

AU - Satapoomin, Aim

AU - Dulyayangkul, Punyawee

AU - Avison, Matthew B

N1 - Funding Information: This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research. N.S. received a postgraduate scholarship from the University of Bristol. We declare no conflicts of interest. Publisher Copyright: © 2022 American Society for Microbiology. All rights reserved.

PY - 2022/3/16

Y1 - 2022/3/16

N2 - We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.

AB - We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.

KW - KPC

KW - carbapenemase

U2 - 10.1128/aac.02179-21

DO - 10.1128/aac.02179-21

M3 - Article (Academic Journal)

C2 - 35293781

SN - 0066-4804

VL - 66

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 4

ER -

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

Abstract

Bibliographical note

Keywords

Access to Document

Handle.net

Fingerprint

Cite this